•The combination of neratinib plus dasatinib was highly synergistic across breast cancer subtypes, with particular sensitivity observed in innately trastuzumab-resistant and acquired neratinib-resistant HER2-positive breast cancer models. This evidence concerns the gene ERBB2 and breast carcinoma.